NCT07211542View on ClinicalTrials.gov

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

September 30, 2026

Conditions

Moderate-to-severe Atopic Dermatitis

Interventions

DRUG

SHR-1905 Injection

SHR-1905 injection.

DRUG

SHR-1905 Injection Blank Preparation

SHR-1905 injection blank preparation.

Trial Locations (1)

510091

Dermatology Hospital of Southern Medical University, Guangzhou

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY

NCT07211542 - A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter